US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Champion Industries, Inc.

0.0001

+0.0000

Volume:- -

Turnover:- -

Market Cap:5.59

PE:0.00

High:0.0001

Open:0.0001

Low:0.0001

Close:0.0001

Loading ...

Overview Company News Filings

AbbVie announces CHMP opinion recommending approval of upadacitinib

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

Press Release: BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term?

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Royalty Pharma Reports Q4 and Full Year 2024 Results

CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi

BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi

MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug

AstraZeneca’s Imfinzi recommended for approval in EU by CHMP

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses

Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.0001,"timestamp":1744920000000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Market Closed","change":0,"latestTime":"04-17 16:00:00 EDT Delay","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":2.7777835648268714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"volumeRatio":2.7777835648268714,"shares":55857,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.0001,"institutionHeld":0,"latestPrice":0.0001,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.0001,"prevYearClose":0.0001,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514411843","title":"AbbVie announces CHMP opinion recommending approval of upadacitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2514411843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514411843?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:15","pubTimestamp":1740737725,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion recommending the app...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-announces-chmp-opinion-recommending-approval-of-upadacitinib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-announces-chmp-opinion-recommending-approval-of-upadacitinib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0310799852.SGD","LU1093756325.SGD","LU2133065610.SGD","LU0738911758.USD","IE00BDGV0183.EUR","LU1496350502.SGD","LU0256863811.USD","SG9999011175.SGD","IE00B4R5TH58.HKD","SG9999015952.SGD","IE00BVYPNW00.USD","LU1023059063.AUD","LU1934455277.USD","LU1244550577.SGD","LU1057294990.SGD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU1989771016.USD","IE00B42XCP33.USD","IE0004445239.USD","IE0009355771.USD","LU0170899867.USD","LU0882574055.USD","LU0198837287.USD","LU0661504455.SGD","LU0234572021.USD","LU0203347892.USD","LU0820561818.USD","LU0114720955.EUR","LU1003077747.HKD","ABBV","LU0128525929.USD","SG9999003800.SGD","LU0545039389.USD","LU2112291526.USD","LU0985320562.USD","LU0949170772.SGD","LU2237443895.HKD","LU0211327993.USD","LU0943347566.SGD","LU1093756168.USD","LU2089283258.USD","LU1037948897.HKD","LU1989772840.SGD","BK4550","IE0002141913.USD","LU1551013425.SGD","LU2468319806.SGD","CHMP","LU1732799900.SGD"],"gpt_icon":0},{"id":"2514313647","title":"AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514313647","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514313647?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:00","pubTimestamp":1740726000,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the pivotal Phase 3SELECT-GCA trial that evaluated the efficacy and safety ofupadacitinib in adults with giant cell arteritis 1. The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission, were met1. GCAis an autoimmune disease that causes inflammation of the large and medium cranial arteries, resulting in potentially debilitating symptoms2. NORTH CHICAGO, Ill., Feb. 28, 2025 /PRNewswire/ -- AbbVie  today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  adopted a positive opinion recommending the approval of upadacitinib for the treatment of adult patients with GCA. The final European Commission decision is expected in the first half of 2025. If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA.*Sustained remission is defined as having ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1061106388.HKD","LU0256863902.USD","SG9999001440.SGD","LU0708994859.HKD","SG9999003800.SGD","LU0949170772.SGD","BK4581","LU0661504455.SGD","CPK","TAK","LU0545039389.USD","LU2237443382.USD","LU2468319806.SGD","BK4139","LU1989771016.USD","LU0122379950.USD","LU0861579265.USD","LU0795875086.SGD","LU1267930573.SGD","LU0882574055.USD","LU0114720955.EUR","LU0820561818.USD","LU2237443895.HKD","LU0689472784.USD","LU1244550221.USD","LU1718418525.SGD","LU2237443978.SGD","LU1003077747.HKD","CHMP","LU2347655156.SGD","LU1551013342.USD","BK4197","ALT","BK4566","IE00BJJMRZ35.SGD","LU0553294199.USD","LU1585245621.USD","BK4534","BK4007","BK4599","ABBV","LU1934455863.HKD","LU1878469433.USD","RA","LU0198837287.USD","LU0943347566.SGD","BK4588","LU1037948541.HKD","LU0417517546.SGD"],"gpt_icon":0},{"id":"2514885330","title":"Cytokinetics Reports Fourth Quarter 2024 Financial Results  and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514885330","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514885330?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:00","pubTimestamp":1740690000,"startTime":"0","endTime":"0","summary":"Commercial Launch Preparations Advancing Prior to September 26 PDUFA Date;Regulatory Filings Under Review in U.S., Europe and China. Topline Results from MAPLE-HCM Expected in Q2 2025. Company Provides 2025 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2024. SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025  -- Cytokinetics, Incorporated  reported a management update and financial results for the fourth quarter and full year of 2024. The company also provided full year 2025 financial guidance.The Center for Drug Evaluation  oftheChina National Medical Products Administration  accepted the NDA foraficamtenforthe treatment of obstructive HCM with Priority Review. We are responding to information requests from the NMPA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytokinetics-reports-fourth-quarter-2024-210000423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4087","BK4017","BK4531","BK4588","MAA","BK4585","CDE","BK4215","CHMP","BK4007","CYTK","BK4505","BK4139","HCM"],"gpt_icon":0},{"id":"2514550806","title":"Ligand Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514550806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514550806?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033694/0/en/Ligand-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLM","FSGS","LU2237438978.USD","BK4201","BK4585","EC","CHMP","LU0053666078.USD","BK4087","BK4588","BK4011","SG9999001077.SGD","BK4548","BK4156"],"gpt_icon":0},{"id":"2514852178","title":"Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2514852178","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514852178?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:19","pubTimestamp":1740579540,"startTime":"0","endTime":"0","summary":"It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus.bluebird bio’s BLUE shares plunged after the company announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle and SK Capital Partners, LP.Gilead Sciences, Inc. GILD announced that the European Medicines Agency  has validated the company’s marketing authorization application and EU-Medicines for all applications for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Gilead is seeking approval for lenacapavir for the prevention of HIV as pre-exposure prophylaxis .Both these applications are being assessed under an accelerated assessment review timeline as the EMA’s Committee for Medicinal Products for Human Use  determined that twice-yearly lenacapavir for HIV prevention is a product of major interest for public health and therapeutic innovation.BioMarin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-blue-down-141900146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU1571399168.USD","IE00BKVL7J92.USD","BK4585","LU1430594728.SGD","BK4568","LU0058720904.USD","BK4087","BK4550","IE00B19Z3B42.SGD","LU1066053197.SGD","GILD","LU1066051498.USD","IE00BSNM7G36.USD","BK4532","LU0234570918.USD","LU1839511570.USD","IE00B3T34201.USD","BK4583","TRDA","BK4566","BLUE","LU2087621335.USD","LU1585245621.USD","BMRN","IE0002270589.USD","LU0109394709.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4139","LU2089984988.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4578","LU0889565916.HKD","BK4588","CHMP","BK4556"],"gpt_icon":0},{"id":"2514324688","title":"Press Release: BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514324688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514324688?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"Proceeds to support advancement of BX004 program through Phase 2b study topline results. in cystic fibrosis  patients, anticipated in Q1 2026. Financing will also support analysis of real-world evidence in people with CF to explore. the relationship between P. aeruginosa reduction and clinical outcomes. Laidlaw & Company  Ltd. acted as sole placement agent for the Offerings. Haynes and Boone, LLP served as legal counsel to BiomX. Sullivan & Worcester LLP served as legal counsel to Laidlaw.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHGE","BK4233","BK4205","BK4585","UK","BK4139","BK4528","CHMP","CF","BK4087","BK4093","BK4588"],"gpt_icon":0},{"id":"2514483443","title":"Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514483443","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514483443?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:30","pubTimestamp":1740573000,"startTime":"0","endTime":"0","summary":"Achieved $47.5 million in RYTELO  net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval. Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met. FOSTER CITY, Calif., February 26, 2025----Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights.Continued execution on U.S. commercial launch, with net product revenue for RYTELO  of $47.5 million in the fourth quarter of 2024 and $76.5 million since launch at the end of June 2024, following approval by the U.S. Food and Drug Administration .Presented new data at the 66th American Society for Hematology  Annual Meeting in December 2024, including analyses of IMerge Phase 3 data suggesting clinical activity o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-reports-fourth-quarter-123000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4087","OS","ASH","CHMP","BK4097","BK4109","LU2463526074.USD","GERN"],"gpt_icon":0},{"id":"2514203201","title":"Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2514203201","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514203201?lang=en_us&edition=fundamental","pubTime":"2025-02-25 14:00","pubTimestamp":1740463200,"startTime":"0","endTime":"0","summary":"Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-income countries.COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S  today announced a strategic partnership with Biological E. Limited  to expand access to Bavarian Nordic’s chikungunya vaccine in low- and middle-income  countries.“We are pleased to announce our first collaboration to expand global access to our chikungunya vaccine and also our first partnership with Biological E, who have solid expertise and comprehensive experience in supplying vaccines for improving public health worldwide,” said Paul Chaplin, President & CEO of Bavarian Nordic. “Expanding supply is a prerequisite for our ability to address the increasing need for solutions to prevent chikungunya in vulnerable populations in endemic regions, and we are dedicated to pursuing strong partnerships that can help us achieve this goal.”While the mechanism of ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bavarian-nordic-partners-biological-e-060000309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0444973449.USD","LU0957808578.USD","BK4541","BK4182","LU2249611893.SGD","LU2357125470.USD","BK4139","LU1642822529.SGD","LU2294711713.HKD","LU0823414478.USD","BK4585","BVNKF","BVNRY","LU0444971666.USD","LU1815336760.USD","BK4588","LU2506951792.HKD","CHMP","LU0476273544.USD","BE","BK4087","LU0823414551.USD"],"gpt_icon":0},{"id":"2513210957","title":"European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2513210957","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513210957?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries –。The EMA validation follows the announcement last week that the U.S. Food and Drug and Administration  accepted Gilead’s New Drug Applications  for lenacapavir for PrEP and will assess them under priority review.The EMA applications are supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead. In PURPOSE 1 , data showed twice-yearly lenacapavir demonstrated zero infections in the lenacapavir group and 100% risk reduction and superiority compared to background HIV incidence  for the investigational use of HIV prevention in cisgender women. In PURPOSE 2 , there were two HIV infections in the lenacapavir group, demonstrating 99.9% of participants in the lenacapavir group did not acquire HIV infection, a 96% risk reduction in HIV infections, and superiority compared to bHIV among a broad and geographically diverse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-validates-gilead-133000551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00B19Z3B42.SGD","LU1839511570.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","BK4585","LU0234570918.USD","GILD","LU0889565916.HKD","LU2089984988.USD","LU0289739699.SGD","BK4583","BK4550","IE00BZ1G4Q59.USD","LU1066053197.SGD","BK4139","IE00B19Z3581.USD","LU1066051498.USD","CHMP","BK4532","LU0109394709.USD","LU1571399168.USD","BK4215","LU2087621335.USD","BK4566","LU1585245621.USD","BK4156","MAA","IE00BSNM7G36.USD","IE00BKVL7J92.USD","LU0058720904.USD","LU1430594728.SGD","MDCO","LU2468319806.SGD","BK4568","IE0002270589.USD","BK4087","BK4578","LU0320765992.SGD"],"gpt_icon":0},{"id":"2513676452","title":"Is Johnson & Johnson (JNJ) the Best Non-Tech Stock to Buy Now for Long Term?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513676452","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513676452?lang=en_us&edition=fundamental","pubTime":"2025-02-21 20:52","pubTimestamp":1740142363,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term.In this article, we are going to take a look at where Johnson & Johnson  stands against the other non-tech stocks.Investing in non-technology stocks offers a range of benefits that can enhance an investor's portfolio, providing diversification, stability, and exposure to sectors with strong growth potential. While technology companies have often dominated headlines with rapid growth, non-tech sectors have demonstrated robust performance and present compelling opportunities for investors. Diversification is a fundamental principle in investment strategy, aiming to reduce exposure to any single asset or sector. By allocating capital across various industries, investors can mitigate the impact of a downturn in any one area. Non-tech stocks, encompassing sectors such as finance, healthcare, consumer goods, and energy, often exhibit different performance cycles compared to technology stocks. This lack of per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-jnj-best-non-125243829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1674673428.USD","BK4592","LU0058720904.USD","LU0345770308.USD","LU0122379950.USD","LU2112291526.USD","LU2430703251.USD","IE00BSNM7G36.USD","LU1261432733.SGD","LU0203347892.USD","LU1506573853.SGD","LU1059921491.USD","LU1430594728.SGD","LU1074936037.SGD","SG9999002224.SGD","LU1244550494.USD","LU0882574055.USD","IE00B42XCP33.USD","LU1221951046.USD","LU1162221912.USD","LU1221951129.SGD","LU1914381329.SGD","BK4585","LU1674673691.USD","LU1061106388.HKD","IE00BDGV0183.EUR","LU1778281490.HKD","IE00B19Z3581.USD","BK4007","LU0289739699.SGD","LU1585245621.USD","BK4588","LU1196500208.SGD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00BJJMRZ35.SGD","LU0098860793.USD","LU1935042991.SGD","LU2347655156.SGD","LU0345769631.USD","LU2592432038.USD","CHMP","LU1066051811.HKD","LU1244550221.USD","LU0345770993.USD","IE00B4R5TH58.HKD","LU1894683264.USD","JNJ","LU1280957306.USD","IE00BGHQF631.EUR"],"gpt_icon":0},{"id":"2512610976","title":"X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2512610976","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512610976?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:35","pubTimestamp":1739968500,"startTime":"0","endTime":"0","summary":"Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and EgyptBOSTON and DUBAI, United Arab Emirates, Feb.  19, 2025  (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3028683/0/en/X4-Pharmaceuticals-and-taiba-rare-Announce-Exclusive-Agreement-for-the-Distribution-and-Commercialization-of-XOLREMDI-mavorixafor-in-WHIM-Syndrome-in-Select-Middle-East-Countries.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","SLCT","BK4588","MAA","BK4087","BK4215","BK4585"],"gpt_icon":0},{"id":"2510888943","title":"Royalty Pharma Reports Q4 and Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2510888943","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510888943?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:15","pubTimestamp":1739276100,"startTime":"0","endTime":"0","summary":"Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in Q","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024051/0/en/Royalty-Pharma-Reports-Q4-and-Full-Year-2024-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","CHMP"],"gpt_icon":0},{"id":"2509644462","title":"CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2509644462","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509644462?lang=en_us&edition=fundamental","pubTime":"2025-02-05 00:07","pubTimestamp":1738685220,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the European Medicines Agency’s  Committee for Medicinal Products for Human Use  rendered a positive opinion for the expanded use of the subcutaneous  formulation of Rybrevant  in advanced EGFR-mutated non-small cell lung cancer .The CHMP recommendation is for SC Rybrevant in combination with Lazcluze  for the first-line treatment of patients with advanced NSCLC with EGFR exon 19 deletion  or L858R mutation. The CHMP also recommended marketing authorization for the SC formulation of Rybrevant as a monotherapy for treating adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum-based therapy.The European Commission had approved a combination of its intravenously administered Rybrevant plus Lazcluze for a similar use in Europe in December 2024.In the past year, shares of J&J have lost 2.5% compared with the industry’s decline of 2.6%.CHMP Nod to JNJ's Rybrevant Based on Data From PALOMA-3 Study. Im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-gives-nod-expanded-j-160700577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889566641.SGD","LU0345769128.USD","IE0009355771.USD","LU1244550577.SGD","LU1585245621.USD","LU0889565916.HKD","LU2347655156.SGD","LU2417539215.USD","LU1061106388.HKD","IE0034235303.USD","BK4581","IE00BSNM7G36.USD","BK4181","IE00BGHQF631.EUR","LU0466842654.USD","SG9999002224.SGD","BK4533","AZN","IE00BJJMRZ35.SGD","BK4087","BK4213","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1914381329.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","LU1674673691.USD","LU0795875169.SGD","LU2089984988.USD","LU0203347892.USD","BK4585","JNJ","LU0234572021.USD","LU1066053197.SGD","LU1023059063.AUD","CHMP","IE0002270589.USD","LU1059921491.USD","LU0912757837.SGD","BK4534","BMRN","CRT","IE00B7SZLL34.SGD","HRMY","LU0320765646.SGD","PK","LU2505996509.AUD","LU1261432733.SGD","BK4139","LU1162221912.USD"],"gpt_icon":0},{"id":"2508120507","title":"BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2508120507","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508120507?lang=en_us&edition=fundamental","pubTime":"2025-02-04 02:34","pubTimestamp":1738607640,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb BMY announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use  of the European Medicines Agency for two of its drugs.The CHMP recommended approval of Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .The CHMP also recommended approval of Breyanzi  for relapsed or refractory follicular lymphoma.Shares of BMY have risen 29.8% in the past year against the industry’s decline of 8.7%.The positive CHMP opinion was based on late-stage CheckMate -9DW trial, which demonstrated statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in RCC patients.We note that Breyanzi is currently approved in the EU for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , high-grade B-cell lymphoma , primary mediastinal ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bmy-gets-positive-chmp-opinion-183400618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","IE00BJJMRZ35.SGD","LU0225284248.USD","LU1291159041.SGD","LU0456855351.SGD","CHMP","LU0306806265.USD","LU2125154935.USD","LU2242652126.USD","LU2133065610.SGD","LU1323610961.USD","LU1868836914.USD","ALNY","LU1670710661.SGD","BMY","IE00B2B36J28.USD","LU1989771016.USD","HCC","IE00B7SZLL34.SGD","BK4532","LU1670710588.SGD","LU2360032135.SGD","BK4588","LU1093756168.USD","BK4022","IE00BFTCPJ56.SGD","LU0096364046.USD","LU0321505439.SGD","BK4006","LU0882574055.USD","LU1261432733.SGD","IE0002141913.USD","IE0002270589.USD","LU1585245621.USD","IE0009355771.USD","LU1074936037.SGD","LU1868837300.USD","LU2242646821.SGD","CAR","LU1670711040.USD","LU0225771236.USD","BMRN","IE00B19Z3581.USD","LU1868837136.USD","LU1718418525.SGD","BK4007","EXEL","BK4548","LU0985481810.HKD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2508312972","title":"MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive","url":"https://stock-news.laohu8.com/highlight/detail?id=2508312972","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508312972?lang=en_us&edition=fundamental","pubTime":"2025-02-04 00:22","pubTimestamp":1738599720,"startTime":"0","endTime":"0","summary":"Merck MRK announced that the European Medicines Agency’s  Committee for Medicinal Products for Human Use  has recommended the approval of its 21-valent pneumococcal conjugate vaccine , Capvaxive, for the prevention of invasive pneumococcal disease  and pneumococcal pneumonia in individuals aged 18 years and above.The European Commission will now review the CHMP’s opinion and a final decision from the regulatory body is expected by the second quarter of 2025.The FDA approved Capvaxive for 21 serotypes, which account for 84% of all IPDs in older adults, in June 2024.Capvaxive targets serotypes that account for approximately 84% of all IPD in older adults  in the United States, including eight serotypes not covered by currently licensed vaccines.In the past year, shares of Merck have plunged 21.7% compared with the industry’s decrease of 2.6%.A potential approval in the EU will mark the fourth authorization of Capvaxive for the prevention of IPD and pneumococcal pneumonia in adults.Once t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mrk-gets-positive-chmp-nod-162200228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0965509283.SGD","LU1093756168.USD","IE000M9KFDE8.USD","SG9999014559.SGD","LU0456855351.SGD","SNY","IE0002141913.USD","LU1162221912.USD","LU1571399168.USD","LU0321505868.SGD","LU1093756325.SGD","LU1057294990.SGD","LU1974910355.USD","SG9999015341.SGD","MRK","IE0009354923.USD","LU1066051225.USD","BK4585","LU1116320737.USD","PCVX","LU1894683264.USD","IE00BJT1NW94.SGD","PFE","SG9999002224.SGD","IE00BLSP4239.USD","LU1934455194.USD","BK4516","LU2089984988.USD","LU1989772840.SGD","LU0985481810.HKD","LU1291159041.SGD","LU0106261372.USD","LU2106854487.HKD","LU0320765489.SGD","SG9999011175.SGD","BK4592","LU0289739699.SGD","LU1934455277.USD","LU1037948897.HKD","SGXZ57979304.SGD","LU0861579265.USD","LU1116320901.HKD","SG9999014575.USD","LU1430594728.SGD","SG9999002232.USD","LU1066051811.HKD","SG9999014542.SGD","LU0006306889.USD","CHMP","IE00BSNM7G36.USD"],"gpt_icon":1},{"id":"2508746140","title":"Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2508746140","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508746140?lang=en_us&edition=fundamental","pubTime":"2025-02-03 22:31","pubTimestamp":1738593060,"startTime":"0","endTime":"0","summary":"BiogenBIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi  for mild cognitive impairment due to Alzheimer’s disease  and mild AD, collectively known as early AD, in the EU.Please note that, in November 2024, the European Medicines Agency’s  Committee for Medicinal Products for Human Use  rendered a positive opinion recommending marketing approval for Leqembi for early AD.Biogen and Eisai announced that the European Commission  has requested the CHMP to reassess new safety data that emerged after the positive opinion and determine if any updates are needed. Additionally, the CHMP will review the clarity of risk minimization measures in its opinion to ensure proper implementation. These discussions are scheduled for an upcoming CHMP meeting later this month.BIIB stock lost 1.6% on Friday following the news. Shares of Biogen have plunged 17.1% in the past three months compared with theindustry’s decline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-stock-down-regulatory-eu-143100317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0203201768.USD","LU0466842654.USD","SG9999018865.SGD","LU0061475181.USD","LU1093756325.SGD","LU2357305700.SGD","LU0471298777.SGD","LU2491050071.SGD","LU2106854487.HKD","BIIB","LU2265009873.SGD","LU0689472784.USD","LU1720051108.HKD","LU0943347566.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","PRTA","BK4533","LU1023059063.AUD","BK4201","LU1069344957.HKD","LLY","LU2237443382.USD","LU2211815571.USD","GB00BDT5M118.USD","LU1623119135.USD","LU0289739699.SGD","LU0079474960.USD","LU0114720955.EUR","LU0198837287.USD","LU1366192091.USD","LU1548497426.USD","LU0456855351.SGD","IE00BFTCPJ56.SGD","LU1868836591.USD","EC","LU1280957306.USD","LU2237443622.USD","BK4139","SG9999014898.SGD","CSTL","IE0009355771.USD","CHMP","LU2361044865.SGD","SG9999014880.SGD","LU0354030438.USD","LU0820561818.USD","SG9999014914.USD"],"gpt_icon":1},{"id":"2508111697","title":"AstraZeneca’s Imfinzi recommended for approval in EU by CHMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2508111697","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508111697?lang=en_us&edition=fundamental","pubTime":"2025-02-03 19:25","pubTimestamp":1738581919,"startTime":"0","endTime":"0","summary":"AstraZeneca’s (AZN) Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with limited-st...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazenecas-imfinzi-recommended-for-approval-in-eu-by-chmp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazenecas-imfinzi-recommended-for-approval-in-eu-by-chmp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2417539215.USD","BK4568","LU2456880835.USD","BK4588","AZN","LU0320765992.SGD","LU1829250122.USD","BK4585","LU2462157665.USD","LU0109394709.USD","CHMP","LU2236285917.USD","BK4007","BK4087","LU0889565916.HKD","BK4156"],"gpt_icon":0},{"id":"2507957937","title":"Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2507957937","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507957937?lang=en_us&edition=fundamental","pubTime":"2025-01-31 21:00","pubTimestamp":1738328400,"startTime":"0","endTime":"0","summary":"Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease progression or death by 37% versus chemotherapy. Datopotamab deruxtecan approved in the U.S. and Japan for same patient population. TOKYO & MUNICH, January 31, 2025----Datopotamab deruxtecan  has been recommended for approval in the European Union  for the treatment of adult patients with unresectable or metastatic hormone receptor  positive, HER2 negative  breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.Datopotamab deruxtecan demonstrated a favorable safety profile over chemotherapy with no new safety concerns identified. Grade 3 or higher treatment-related adverse events  occurred in 21% and 45% of patients in the datopotamab deruxtecan and chemotherapy arms, respectively. The most common grade 3 or higher TRAEs were neutropenia , stomatitis , fatigue  and anemia . In the datopotamab de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-recommended-approval-eu-130000461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBD","BK4195","BK4203","BK4161","HR","BK4225","BK4007","BK4213","ADC","ORR","BK4087","PFS","DSKYF","BK4080","CR","BK4231","DSNKY","BK4211","BK4156","PR","CHMP"],"gpt_icon":0},{"id":"2507952717","title":"Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses","url":"https://stock-news.laohu8.com/highlight/detail?id=2507952717","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507952717?lang=en_us&edition=fundamental","pubTime":"2025-01-31 20:52","pubTimestamp":1738327920,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb said a key European regulatory committee is backing expanded approvals for its CAR-T cell therapy Breyanzi and its Opdivo plus Yervoy cancer-drug combination.Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy.Breyanzi is already approved in several lymphoma indications in Europe.The Princeton, N.J., biopharmaceutical company said the CHMP also recommended approval of Opdivo plus Yervoy for the first-line treatment of adults with unresectable or advanced hepatocellular carcinoma, which accounts for up to 85% of all liver cancers.The Opdivo/Yervoy combination is already approved in several cancer indications in Europe.The European Commission, which generally follows CHMP's advice, will now review the recommendations, with its decisions expecte","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU1074936037.SGD","BK4559","LU1291159041.SGD","LU1323610961.USD","LU2360032135.SGD","LU0237698245.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU0321505868.SGD","LU1670711040.USD","BK4585","BK4534","LU1868836591.USD","BK4007","IE0002141913.USD","LU1670710588.SGD","LU1989771016.USD","MYE","BK4581","LU0868494617.USD","BMY","LU0306807586.USD","LU1571399168.USD","LU1868837136.USD","LU1670710661.SGD","LU0882574055.USD","BK4087","LU0456855351.SGD","LU1032466523.USD","LU1430594728.SGD","LU2125154778.USD","IE0009355771.USD","LU1868836757.USD","LU2242646821.SGD","LU2242652126.USD","LU1868836914.USD","LU0306806265.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0061475181.USD","LU2133065610.SGD","LU1718418525.SGD","LU0096364046.USD","BK4126","LU0985481810.HKD","LU0225284248.USD","CHMP","BK4588","LU1670711123.USD"],"gpt_icon":0},{"id":"2507547809","title":"Biogen, Eisai: EC Asks CHMP to Take Another Look at Leqembi","url":"https://stock-news.laohu8.com/highlight/detail?id=2507547809","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507547809?lang=en_us&edition=fundamental","pubTime":"2025-01-31 20:14","pubTimestamp":1738325640,"startTime":"0","endTime":"0","summary":"Biogen and Eisai have hit another bump in their quest to win European regulatory approval of their Alzheimer's drug Leqembi.The companies on Friday said the European Commission has asked the Committee for Medicinal Products for Human Use to consider information on the safety of the drug that became available after the panel finally adopted a positive opinion in November.The commission wants the CHMP to consider whether the information may require an update of the positive opinion, and to consider whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation, the companies added.The CHMP last July recommended against approval of Leqembi, citing safety and efficacy issues, but Biogen and Eisai asked the panel to take another look, and the CHMP in November reversed course and recommended approving the drug.At the time, Biogen and Eisai said they expected the European Commission, which generally follows the CHMP's advice, to make a fi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4139","EC","IE00B19Z9P08.USD","BK4087","CHMP","BK4532","BK4588","IE00B894F039.SGD","BK4533","IE00B19Z9Z06.USD","LU0109394709.USD","LU0234570918.USD","BK4201","LU0320765992.SGD","BK4585","LU0889565916.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":126,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{}}}